Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 101–200 of 1,000
Heart failure with reduced ejection fraction
Bloom, M. W., Greenberg, B., Jaarsma, T., Januzzi, J. L., Lam, C. S. P., Maggioni, A. P., Trochu, J.-N., & Butler, J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.58 · Cited by 222
The Heart Failure Revascularisation Trial (HEART)
Cleland, J. G. F., Calvert, M., Freemantle, N., Arrow, Y., Ball, S. G., Bonser, R. S., Chattopadhyay, S., Norell, M. S., Pennell, D. J., & Senior, R. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq230 · Cited by 233
Self-citationAimo, A., Januzzi, J. L., Vergaro, G., Ripoli, A., Latini, R., Masson, S., Magnoli, M., Anand, I. S., Cohn, J. N., Tavazzi, L., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031560 · Cited by 221
van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., Muntendam, P., van Veldhuisen, D. J., & de Boer, R. A. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000129 · Cited by 216
Self-citationBiological Phenotypes of Heart Failure With Preserved Ejection Fraction
Lewis, G. A., Schelbert, E. B., Williams, S. G., Cunnington, C., Ahmed, F., McDonagh, T. A., & Miller, C. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.006 · Cited by 214
Colombo, P. C., Ganda, A., Lin, J., Onat, D., Harxhi, A., Iyasere, J. E., Uriel, N., & Cotter, G. (2012) · Heart Failure Reviews · doi:10.1007/s10741-011-9261-3 · Cited by 210
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Molyneux, S. L., Florkowski, C. M., George, P. M., Pilbrow, A. P., Frampton, C. M., Lever, M., & Richards, A. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.044 · Cited by 209
Voors, A. A., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., van der Harst, P., Hillege, H. L., Lang, C. C., ter Maaten, J. M., Ng, L., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.531 · Cited by 204
Self-citationCleland, J. G. F., McMurray, J. J. V., Kjekshus, J., Cornel, J. H., Dunselman, P., Fonseca, C., Hjalmarson, Å., Korewicki, J., Lindberg, M., Ranjith, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.041 · Cited by 203
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 190
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Self-citationInflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2025) · JACC · doi:10.1016/j.jacc.2025.08.047 · Cited by 177
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Preiss, D., Tikkanen, M. J., Welsh, P., Ford, I., Lovato, L. C., Elam, M. B., LaRosa, J. C., DeMicco, D. A., Colhoun, H. M., Goldenberg, I., et al. (2012) · JAMA · doi:10.1001/jama.2012.8439 · Cited by 181
Self-citationWang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease
Tousoulis, D., Psarros, C., Demosthenous, M., Patel, R., Antoniades, C., & Stefanadis, C. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.054 · Cited by 187
Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis
Hackam, D. G., Woodward, M., Newby, L. K., Bhatt, D. L., Shao, M., Smith, E. E., Donner, A., Mamdani, M., Douketis, J. D., Arima, H., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.055269 · Cited by 187
Baker, W. L., Talati, R., White, C. M., & Coleman, C. I. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.008 · Cited by 187
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Lam, C. S. P., Chandramouli, C., Ahooja, V., & Verma, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013389 · Cited by 183
“As previously discussed, a meta-analysis of EMPAREG OUTCOME, CANVAS, and DECLARE-TIMI 58 demonstrated cardiovascular benefit with SGLT-2 inhibitors in patients with and without a history of HF.56 Moreover, subanalyses of the EMPA-REG OUTCOME and CANVAS trials demonstrated that the ARR in hHF may be greater in patients…”
MethodInfluentialAvan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182
“However, in the same trials, rosuvastatin significantly decreased the rate of cardiovascular hospitalizations and it did not decrease the primary outcome (Kjekshus et al., 2007; Nakou et al., 2008).”
BackgroundEffects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
McTaggart, F., & Jones, P. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6113-z · Cited by 177
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.115 · Cited by 175
Self-citationEffect of statin therapy on colorectal cancer
Bardou, M., Barkun, A., & Martel, M. (2010) · Gut · doi:10.1136/gut.2009.190900 · Cited by 175
Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019) · Circulation Research · doi:10.1161/circresaha.118.313568 · Cited by 176
“However, the CORONA (Controlled Rosuvastatin Multinational Trial in HF) compared rosuvastatin versus placebo in patients with ischemic cardiomyopathy and HFrEF.(95) At 33 months (median follow-up), rosuvastatin, compared with placebo, did not reduce the primary outcome, a composite of nonfatal MI, nonfatal stroke, and…”
ResultInfluentialBriasoulis, A., Androulakis, E., Christophides, T., & Tousoulis, D. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9533-z · Cited by 174
Newman, C. B., Blaha, M. J., Boord, J. B., Cariou, B., Chait, A., Fein, H. G., Ginsberg, H. N., Goldberg, I. J., Murad, M. H., Subramanian, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa674 · Cited by 172
Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
Lazar, L. D., Pletcher, M. J., Coxson, P. G., Bibbins-Domingo, K., & Goldman, L. (2011) · Circulation · doi:10.1161/circulationaha.110.986349 · Cited by 174
III Diretriz Brasileira de Insuficiência Cardíaca Crônica
Bocchi, E. A., Marcondes‐Braga, F. G., Ayub‐Ferreira, S. M., Rohde, L. E. P., Junior, W. A. D. O., Almeida, D. R., Moreira, M. D. C. V., Bestetti, R. B., Bordignon, S., Azevedo, C., et al. (2009) · Americanae (AECID Library) · doi:10.1590/s0066-782x2009002000001 · Cited by 170
Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review
Araújo, J. P., Lourenço, P., Azevedo, A., Friões, F., Rocha-Gonçalves, F., Ferreira, A., & Bettencourt, P. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.030 · Cited by 173
Antonopoulos, A. S., Margaritis, M., Verheule, S., Recalde, A., Sanna, F., Herdman, L., Psarros, C., Nasrallah, H., Coutinho, P., Akoumianakis, I., et al. (2016) · Circulation Research · doi:10.1161/circresaha.115.307856 · Cited by 171
Yeganeh, B., Wiechec, E., Ande, S. R., Sharma, P., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
“86 Wikstrand, J. (2007). Rosuvastatin in older patients with systolic heart failure.”
BackgroundDelahoy, P. J., Magliano, D. J., Webb, K., Grobler, M., & Liew, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.017 · Cited by 168
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis
Su, X., Zhang, L., Lv, J., Wang, J., Hou, W., Xie, X., & Zhang, H. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.01.016 · Cited by 166
Relations of Lipid Concentrations to Heart Failure Incidence: The Framingham Heart Study
Velagaleti, R. S., Massaro, J., Vasan, R. S., Robins, S. J., Kannel, W. B., & Levy, D. (2009) · Circulation · doi:10.1161/circulationaha.109.830984 · Cited by 165
Jafri, H., Alsheikh-Ali, A. A., & Karas, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.069 · Cited by 162
McMurray, J. J. V., Kjekshus, J., Gullestad, L., Dunselman, P., Hjalmarson, A., Wedel, H., Lindberg, M., Waagstein, F., Grande, P., Hradec, J., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.849117 · Cited by 163
Self-citationReith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00040-8 · Cited by 161
Self-citationKrum, H., & Abraham, W. T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60236-1 · Cited by 159
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Luvai, A., Mbagaya, W., Hall, A. S., & Barth, J. H. (2012) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s4324 · Cited by 189
Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets
Reina‐Couto, M., Pereira‐Terra, P., Quelhas‐Santos, J., Silva-Pereira, C., Albino‐Teixeira, A., & Sousa, T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.746494 · Cited by 180
Gullestad, L. L., Ueland, T., KJEKSHUS, J. K., Nymo, S. H., Hulthe, J., Muntendam, P., Adourian, A. S., Böhm, M., van Veldhuisen, D. J., Michel Komajda, N., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs077 · Cited by 167
Self-citationFink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00008 · Cited by 154
Wedel, H., McMurray, J. J. V., Lindberg, M., Wikstrand, J., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Hjalmarson, Å., Kjekshus, J., Komajda, M., et al. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn046 · Cited by 153
Self-citationA Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease
Lu, F. Y., Murphy, A. J., & Dart, A. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00186 · Cited by 166
Ramasubbu, K., Estep, J. D., White, D. L., Deswal, A. M., & Mann, D. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.009 · Cited by 159
Arterial disease in chronic kidney disease
Moody, W. E., Edwards, N. C., Chue, C. D., Ferro, C. J., & Townend, J. (2012) · Heart · doi:10.1136/heartjnl-2012-302818 · Cited by 162
Heart Failure with Preserved Ejection Fraction: Uncertainties and Dilemmas
Ferrari, R., Böhm, M., Cleland, J. G. F., Paulus, W. J. S., Pieske, B., Rapezzi, C., & Tavazzi, L. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.304 · Cited by 148
Self-citationPetersen, L. K., Christensen, K., & Kragstrup, J. (2010) · Age and Ageing · doi:10.1093/ageing/afq129 · Cited by 149
Pathological Ventricular Remodeling: Therapies: Part 2 of 2
Xie, M., Burchfield, J. S., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001879 · Cited by 171
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
Ravnskov, U., de Lorgeril, M., Diamond, D. M., Hama, R., Hamazaki, T., Hammarskjöld, B., Hynes, N., Kendrick, M. E., Langsjoen, P. H., Mascitelli, L., et al. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1519391 · Cited by 172
“minimize the number of reported side effects; in SAGE [64], serious side effects were recorded in more than 20% in both”
BackgroundResultInfluentialStatin use and the risk of developing diabetes: a network meta‐analysis
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4020 · Cited by 144
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 136
Pugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 144
Self-citationCardiovascular effects of statins, beyond lipid-lowering properties
Mihos, C. G., Pineda, A. M., & Santana, O. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.009 · Cited by 162
Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations
Rogers, J. K., Jhund, P. S., Perez, A.-C., Böhm, M., Cleland, J. G., Gullestad, L., Kjekshus, J., van Veldhuisen, D. J., Wikstrand, J., Wedel, H., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2013.12.007 · Cited by 138
“The design and results of CORONA have been published elsewhere (1,2).”
BackgroundMethodInfluentialSelf-citationThe inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury
Steffens, S., Montecucco, F., & Mach, F. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-12-0837 · Cited by 151
Self-citationWhat causes sudden death in patients with chronic heart failure and a reduced ejection fraction?
Packer, M. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz553 · Cited by 155
Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction
Alogna, A., Koepp, K. E., Sabbah, M., Espindola Netto, J. M., Jensen, M. D., Kirkland, J. L., Lam, C. S. P., Obokata, M., Petrie, M. C., Ridker, P. M., et al. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.06.031 · Cited by 142
Assomull, R. G., Shakespeare, C., Kalra, P. R., Lloyd, G., Gulati, A., Strange, J., Bradlow, W. M., Lyne, J. C., Keegan, J., Poole-Wilson, P. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.011346 · Cited by 137
Hagiwara, N., Kawada-Watanabe, E., Koyanagi, R., Arashi, H., Yamaguchi, J., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endoh, Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx162 · Cited by 136
The Role of Coronary Artery Disease in Heart Failure
Lala, A., & Desai, A. S. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.10.002 · Cited by 168
The STICH Trial (Surgical Treatment for Ischemic Heart Failure)
Carson, P. E., WERTHEIMER, J. H., Miller, A. B., O’Connor, C. M., Piña, I. L., Selzman, C. H., Sueta, C. A., She, L., Greene, D., Lee, K. L., et al. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2013.04.012 · Cited by 158
“There was a low use of ICDs in the STICH trial, which is common among international heart failure trials with enrollment predominantly outside of the United States and Western Europe (26,33).”
BackgroundSoluble ST2 is Associated with Adverse Outcome in Patients with Heart Failure of Ischaemic Aetiology
Broch, K., Ueland, T., Nymo, S. H., KJEKSHUS, J. K., Hulthe, J., Muntendam, P., McMurray, J. J. V., Wikstrand, J., Cleland, J. G. F., Aukrust, P., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs006 · Cited by 132
Self-citationRavassa, S., López, B., Treibel, T. A., José, G. S., Losada-Fuentenebro, B., Tapia, L., Bayés‐Genís, A., Díez, J., & González, A. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101194 · Cited by 152
Torabi, A., Cleland, J. G. F., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J., Rigby, A. S., & Goode, K. M. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn096 · Cited by 135
Self-citationDifferential metabolic effects of distinct statins
Koh, K. K., Sakuma, I., & Quon, M. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.036 · Cited by 130
de Lorgeril, M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.184 · Cited by 130
Biomarkers in heart failure: the past, current and future
Michael, S., Wang, Y., Wei, J., Huang, Y., Li, M., Li, L., Acheampong, E., Zhou, Z., Xiaoyan, Q., Xu, Y., et al. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09807-z · Cited by 153
“HF patients did not result in enhanced consequence [72, 73].”
BackgroundGuía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 177
Self-citationEvaluation and Treatment of Older Patients With Hypercholesterolemia: A Clinical Review
Strandberg, T. E., Kolehmainen, L., & Vuorio, A. (2014) · JAMA · doi:10.1001/jama.2014.10924 · Cited by 127
Cardiovascular effects of flavanol-rich chocolate in patients with heart failure
Flammer, A. J., Sudano, I., Wolfrum, M., Thomas, R., Enseleit, F., Periat, D., Kaiser, P., Hirt, A., Hermann, M., Serafini, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr448 · Cited by 139
Damman, K., Kjekshus, J., Wikstrand, J., Cleland, J. G. F., Komajda, M., Wedel, H., Waagstein, F., & McMurray, J. J. V. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.462 · Cited by 126
Self-citationKey inflammatory mechanisms underlying heart failure
Riehle, C., & Bauersachs, J. K. (2019) · Herz · doi:10.1007/s00059-019-4785-8 · Cited by 138
Flores‐Mateo, G., Grau, M., O’Flaherty, M., Ramos, R., Elosúa, R., Violán, C., Quesada, M., Martí‐Lluch, R., Sala, J., Marrugat, J., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.033 · Cited by 161
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 322
Murarka, S., & Movahed, M. R. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.07.249 · Cited by 139
Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms
Okuyama, H., Langsjoen, P. H., Hamazaki, T., Ogushi, Y., Hama, R., Kobayashi, T., & Uchino, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1011125 · Cited by 122
Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease
He, X., Zeng, H., & Chen, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27200 · Cited by 127
Damman, K., Tang, W. H. W., Felker, G. M., Lassus, J., Zannad, F., Krum, H., & McMurray, J. J. V. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.031 · Cited by 122
Self-citationWriting Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Vallejo‐Vaz, A. J., Seshasai, S. R. K., Kurogi, K., Michishita, I., Nozue, T., Sugiyama, S., Tsimikas, S., Yoshida, H., & Ray, K. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.001 · Cited by 134
Myopathy in older people receiving statin therapy: a systematic review and meta‐analysis
Iwere, R. B., & Hewitt, J. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12687 · Cited by 125
Cosmi, F., Shen, L., Magnoli, M., Abraham, W. T., Anand, I. S., Cleland, J. G., Cohn, J. N., Cosmi, D., De Berardis, G., Dickstein, K., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1146 · Cited by 119
Self-citationRosuvastatin in Diabetic Hemodialysis Patients
Holdaas, H., Holme, I., Schmieder, R. E., Jardine, A. G., Zannad, F., Norby, G. E., & Fellström, B. C. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010090987 · Cited by 118
Cannon, J. A., Shen, L., Jhund, P. S., Kristensen, S. L., Køber, L., Chen, F., Gong, J., Lefkowitz, M. P., Rouleau, J. L., Shi, V. C., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.687 · Cited by 124
Self-citationCoenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure
McMurray, J. J. V., Dunselman, P., Wedel, H., Cleland, J. G. F., Lindberg, M., Hjalmarson, Å., Kjekshus, J., Waagstein, F., Apetrei, E., Barrios, V., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.075 · Cited by 98
Self-citationSampson, U. K., Linton, M. F., & Fazio, S. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283470359 · Cited by 116
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 131
Diastolic Dysfunction: – Potential New Diagnostics and Therapies –
Jeong, E.-M., & Dudley Jr, S. C. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0064 · Cited by 113
yuzefpolskaya, M., Bohn, B., Nasiri, M., Zuver, A. M., Onat, D., Royzman, E. A., Nwokocha, J., Mabasa, M., Pinsino, A., Brunjes, D. L., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.02.004 · Cited by 128
Statins and the risk of new-onset diabetes: a review of recent evidence
Preiss, D., & Sattar, N. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 111
KONES, R. J. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10812 · Cited by 141
Inflammatory cytokines as biomarkers in heart failure
Ueland, T., Gullestad, L. L., Nymo, S. H., Yndestad, A., Aukrust, P., & Askevold, E. T. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.09.001 · Cited by 125
Self-citationCharting a Roadmap for Heart Failure Biomarker Studies
Ahmad, T., Fiuzat, M., Pencina, M. J., Geller, N. L., Zannad, F., Cleland, J. G. F., Snider, J. V., Blankenberg, S., Adams, K. F., Redberg, R. F., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2014.02.005 · Cited by 109
Self-citationFenofibrate: treatment of hyperlipidemia and beyond
Rosenson, R. S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1319 · Cited by 124
Alehagen, U., Benson, L., Edner, M., Dahlström, U., & Lund, L. H. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002143 · Cited by 109
Abdul‐Rahim, A. H., Moreno, A. C. P., Fulton, R. L., Jhund, P. S., Latini, R., Tognoni, G., Wikstrand, J., KJEKSHUS, J. K., Lip, G. Y. H., Maggioni, A. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013760 · Cited by 127
Self-citationPotential novel pharmacological therapies for myocardial remodelling
Landmesser, U., Wollert, K. C., & Drexler, H. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn317 · Cited by 116
Güder, G., Frantz, S., Bauersachs, J. K., Allolio, B., Wanner, C., Koller, M., Ertl, G., Angermann, C. E., & Störk, S. (2009) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.825059 · Cited by 120
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.